Wang Xiaoping, Semba Takashi, Phi Lan Thi Hanh, Chainitikun Sudpreeda, Iwase Toshiaki, Lim Bora, Ueno Naoto T
Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2020 Sep 1;12(9):2479. doi: 10.3390/cancers12092479.
Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2-4% of breast cancer cases are classified as IBC, but-owing to its high rate of metastasis and poor prognosis-8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical studies of targeting these pathways in IBC. We also discuss studies of crosstalk between several signaling pathways and the IBC tumor microenvironment.
炎性乳腺癌（IBC）虽然罕见，但却是最具侵袭性的乳腺癌类型。仅2%-4%的乳腺癌病例被归类为IBC，但其转移率高且预后差，IBC患者的乳腺癌相关死亡率占8%-10%。目前，尚无针对IBC的特异性靶向治疗方法，迫切需要通过了解新靶点来开发新的治疗方法。在本综述中，我们总结了IBC进展过程中关键信号通路的生物学功能以及针对这些通路在IBC中的临床前和临床研究。我们还讨论了几种信号通路与IBC肿瘤微环境之间相互作用的研究。
